---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007487"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T17:03:36.696773+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Passage Bio Q1 2025 net loss $15.4M; cash runway into Q1 2027; first FTD-GRN patient dosed at Dose 2

## Summary
- Net loss of $15.4M ($0.25 per share) vs $16.7M ($0.30 per share) in Q1 2024.
- Cash, cash equivalents and marketable securities $63.4M as of Mar 31, 2025; funding expected into Q1 2027.
- First FTD-GRN patient dosed with Dose 2 PBFT02; second patient enrolled; additional patients being evaluated.
- Enrollment opened for FTD-C9orf72 patients in the upliFT-D study, targeting up to five symptomatic patients.
- R&D expenses decreased to $7.7M from $11.5M; G&A expenses were $6.1M vs $6.5M year-over-year.

## SEC filing metadata
- accession: 0001558370-25-007487
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837025007487/0001558370-25-007487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837025007487/pasg-20250513x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007487
- JSON: https://secwatch.observer/filing/0001558370-25-007487.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.